Pramlintide, a Synthetic Analog of Human Amylin, Improves the Metabolic Profile of Patients With Type 2 Diabetes Using Insulin

Autor: Orville G. Kolterman, S L Schoenfeld, L. Pearson, R. G. Thompson

Publikováno v: Diabetes Care. 21:987-993

OBJECTIVE To examine the effects of 4 weeks of subcutaneous administration of pramlintide, a synthetic analog of human amylin, on metabolic control in patients with type 2 diabetes using insulin. RESEARCH DESIGN AND METHODS Serum fructosamine, HbA1c,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::85dbe7cd37983af776a41ab20f236336
https://doi.org/10.2337/diacare.21.6.987

Are needle-free injections a useful alternative for growth hormone therapy in children? Safety and pharmacokinetics of growth hormone delivered by a new needle-free injection device compared to a fine gauge needle

Autor: A M Wilson, H G Dörr, B K Gillespie, M A van Kuijck, B J Otten, S L Schoenfeld, L Nyman, Eberhard Keller, N R Lester, Cecilia Hyrén, Carl-Joachim Partsch, P Schuld, S Zabransky

Publikováno v: Journal of Pediatric Endocrinology & Metabolism, 16, 3, pp. 383-92
Journal of Pediatric Endocrinology & Metabolism, 16, 383-92

Item does not contain fulltext The clinical safety, use and pharmacokinetics of a new needle-free device for delivery of growth hormone (GH) were compared with those of conventional needle injection devices. In an open-label, randomized, 4-period cro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4242ac4d8b6d02a2cfbd1e4d11e9cd1
https://pubmed.ncbi.nlm.nih.gov/12705363

Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment

Autor: P D, Miller, N B, Watts, A A, Licata, S T, Harris, H K, Genant, R D, Wasnich, P D, Ross, R D, Jackson, M S, Hoseyni, S L, Schoenfeld, D J, Valent, C H, Chesnut

Publikováno v: The American journal of medicine. 103(6)

To determine the efficacy and safety of cyclical etidronate for up to 7 years in the treatment of postmenopausal osteoporosis and to examine the effects of discontinuing treatment after 2 or 5 years of therapy.Patients were randomized at entry into t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::1eabf5ed4c756091a232d5da856b388d
https://pubmed.ncbi.nlm.nih.gov/9428829

First-in-human dose escalation safety and pharmacokinetic (PK) trial of a novel intravenous (IV) thrombospondin-1 (TSP-1) mimetic humanized monoclonal CovX Body (CVX-045) in patients (pts) with advanced solid tumors

Autor: Lee S. Rosen, M. Dinolfo, David S. Mendelson, B. Byrnes, S. L. Schoenfeld, R. B. Cohen, I. K. Bear, Michael S. Gordon

Publikováno v: Journal of Clinical Oncology. 26:3524-3524

3524 Background: CVX-045 is a recombinant humanized monoclonal antibody fused to two TSP-1 mimetic, nonamer peptides. CVX-045 inhibits endothelial cell migration in vitro, and is anti-angiogenic in...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::578119825d34ecd1538e1d8ba76c4271
https://doi.org/10.1200/jco.2008.26.15_suppl.3524